San Diego, CA (PRWEB) May 28, 2015
Today, Proxy Life Science Holdings (Proxy) launched a patent licensing program to enable widely available access of its seminal exosome RNA technology to academia and industry for molecular diagnostic and research tool applications. The company’s Proxysome™ technology allows for detection of genetic markers circulating within blood and other bio-fluids without the need of a tissue biopsy. Proxy’s exosome RNA technology has the potential to identify diseases early, determine molecular susceptibility to treatment, track disease progression and determine the affected organs, all via a simple blood, urine or other “liquid biopsy” method.
Proxy holds the earliest granted patents related to exosomally-derived RNA collection, isolation and amplification. Proxy is making its technologies available under attractive licensing terms via a newly established program. Proxy’s subject patents, US 8,021,847 and US 8,476,017 both entitled “Microvesicle-Based Compositions and Methods“ relate to methods of isolating RNA from blood-borne exosomes and microvesicles for the detection and analysis of disease biomarkers which may then be traced back to the affected cells and organs which produced them.
“By gathering Proxysomes™ via a simple blood draw, information can be accessed about distant cells, tissues and organs, including those originating from a multitude of diseases. Proxysomes™ have been associated with cancers, immunological, cardiovascular, neurological and other conditions. Unlike a tissue biopsy, Proxysomes™ may be collected repeatedly, allowing for the dynamic monitoring of disease progression as well as therapeutic susceptibility and response. These capabilities are just not practical and in most cases not possible with tissue biopsies. Proxy’s Liquid Biopsy method will prove to be an essential healthcare tool” stated Dr. Pietrzkowski, President and Co-founder.
RNA-positive exosomes are widely used in basic and translational research and widely marketed by leading Life Science Tool companies. More recently strides have been made in clinical development for molecular diagnostics especially in cancer. Additionally utility has been found for RNAi therapeutic companion diagnostics, with favorable preclinical results for siRNA, mRNA, microRNA and gene therapy platforms. Concurrently, the rapid adoption of molecular profiling and Next Generation Sequencing (NGS) is accelerating rapidly with the comprehensive and simultaneous interrogation of thousands of gene transcripts at accessible price points. Proxysome™ extracellular RNA technology is highly complementary and enabling to these emergent technologies and each is benefiting from the others’ rapid adoption.
“The Proxysome™ platform is foundational to the field of Liquid Biopsies and promises to become a pillar of precision medicine. Proxy is making the technology widely available via its licensing program and through partnerships as part of our commitment to full realization of exosomes’ potential for human health” stated Mr. Rey Magaña VP and Co-founder.
Most if not all cells in the body are believed to emit genetic and other messaging molecules into the blood stream, urine and other bodily fluids. These emissions are produced by normal cells and tissues but are especially active in response to disease. These molecules are packaged and protected within tiny nano-sized vesicles commonly known as exosomes or microvesicles – proxysomes™. These vesicles and their information rich cargo can travel stealthily throughout the body, delivering messages to distant sites within the body, as depicted by the NIH/NCI video https://commonfund.nih.gov/Exrna/index. The molecules carried by these vesicles include DNA and various species of RNA, both coding and non-coding varieties. They also include proteins, bioactive lipids and metabolites. So far more than 1,200 unique RNA molecules have been discovered including cancer markers such as Her2/neu, BRACA1, EGFR, VEGF, and PCA3. In oncology these vesicles have been linked to breast, prostate, lung, gastric, colorectal, ovarian, pancreatic, and brain cancer among many others. They have also been associated with diseases such as diabetes, cardiovascular disease, Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The technology has potential uses in non-invasive prenatal testing (NIPT). They have been associated with preeclampsia and have been used to determine the stage of pregnancy and even the sex of the fetus. This communication system is important to the establishment and progression of disease but also its Achilles’ heel. This abundant source of information may be readily harvested, decoded and translated to identify disease-related biomarkers, tissue-type biomarkers and their associated bio-signatures, giving Proxysome™ extracellular RNA the potential to replace certain tissue biopsies with a bio-fluid based test.
About Proxy Life Science Holdings
Proxy Life Sciences Holdings, Inc. is a privately held biotechnology company building an IP portfolio focused on exosome-based molecular diagnostics and therapeutics technologies. Its patented Proxysome™ Liquid Biopsy technology forms the core of the company’s research and development program. The company is actively seeking opportunities to out-license or co-develop its technology in the fields of discovery, diagnostics, and therapeutics for application in a wide-ranging set of human diseases and conditions. Visit us at: http://www.proxysome.com
Related Molecular Press Releases